Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...

Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

Each year, Phesi releases an analysis of the world’s most studied diseases. The survey includes data from the 67,569 ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Memphasys Limited (ASX: MEM) has announced the completion of the final patient visit in its pivotal clinical trial for the ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.